Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €53.27 EUR
Change Today -0.02 / -0.04%
Volume 693.0
6MK On Other Exchanges
Symbol
Exchange
New York
Mexico
EN Paris
Sao Paulo
Frankfurt
As of 1:35 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

merck & co. inc. (6MK) Snapshot

Open
€53.26
Previous Close
€53.29
Day High
€53.67
Day Low
€52.70
52 Week High
01/23/15 - €56.15
52 Week Low
05/9/14 - €39.49
Market Cap
150.7B
Average Volume 10 Days
1.7K
EPS TTM
--
Shares Outstanding
2.8B
EX-Date
03/12/15
P/E TM
--
Dividend
€1.84
Dividend Yield
2.74%
Current Stock Chart for MERCK & CO. INC. (6MK)

merck & co. inc. (6MK) Details

Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; antidepressants; ophthalmic and cholesterol modification products; non-sedating antihistamine; and vaginal contraceptive implants. In addition, the company provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; to treat brain tumors and melanoma; to prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers animal health products, including antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for, and vaccines against bacterial and viral disease in fish. Additionally, the company provides companion animal products, such as diabetes mellitus treatment drugs and vaccines for dogs and cats; ointments for acute and chronic otitis; anthelmintic products; chewable tablets to kill fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. The company serves drug wholesalers and retailers, hospitals, government entities and agencies, physicians, physician distributors, veterinarians, distributors, and animal producers, as well as managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

70,000 Employees
Last Reported Date: 02/27/15
Founded in 1891

merck & co. inc. (6MK) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $3.2M
Executive Vice President and President of Mer...
Total Annual Compensation: $1.5M
President of Global Human Health and Executiv...
Total Annual Compensation: $962.4K
Compensation as of Fiscal Year 2014.

merck & co. inc. (6MK) Key Developments

TetraLogic Pharmaceuticals Corporation and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA(R) (Pembrolizumab) in Solid Tumors

TetraLogic Pharmaceuticals Corporation and Merck announced that they have entered into an oncology clinical study collaboration. The companies will collaborate on a Phase 1 study to evaluate the safety and efficacy of birinapant, TetraLogic's SMAC-mimetic, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with relapsed or refractory solid tumors. The study is expected to begin in late 2015. KEYTRUDA and birinapant target different elements of cancer's block against the immune system. TetraLogic's birinapant (TL32711) is a potent, bivalent SMAC-mimetic that binds with differential affinity to multiple members of the IAP family in order to re-establish the immune system's ability to kill abnormal cells via an extracellular TNF signal. Merck's KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2. The proposed collaboration is based on preclinical data that suggest SMAC-mimetics have the potential to enhance existing immuno-oncology agents, such as KEYTRUDA. Under the terms of the agreement, TetraLogic and Merck, through subsidiaries, will collaborate on an initial Phase 1 dose-escalation study of birinapant in combination with KEYTRUDA in patients with relapsed or refractory solid tumors. TetraLogic will sponsor and fund the study and Merck will provide KEYTRUDA. The companies have formed a Joint Development Committee to collaboratively oversee the conduct of the study. Results from the study will be used to determine the path for further clinical development of the combination.

Merck & Co Reports Positive Results for PD-1 Inhibitor Keytruda and Files for Expanded Approval for NSCLC Treatment

Merck & Co has announced that it has filed for expanded regulatory approval of programmed cell death protein 1 (PD-1) inhibitor Keytruda (pembrolizumab) with the US FDA for the treatment of advanced non-small-cell lung cancer (NSCLC) in patients whose disease has progressed on or after platinum-containing chemotherapy, as well as an FDA-approved therapy for epidermal growth factor receptor (EGFR) or ALK genomic tumour aberrations, if applicable. The regulatory filing is based on data from KEYNOTE-001 in patients with greater than or equal to 50% tumour expression of programmed death-ligand 1 (PD-L1) protein. A companion diagnostic test, PD-L1 IHC 22C3 PharmDx, used for detection of PD-L1 expression has also been submitted for approval by Dako North America (subsidiary of Agilent Technologies, US) under a premarket approval application. Meanwhile, Merck has presented new positive results from several studies investigating the safety and efficacy of Keytruda across various indications, including metastatic melanoma, NSCLC, and mesothelioma at the annual meeting of the American Association for Cancer Research in Pennsylvania, US, on 19 April. KEYNOTE-001 in NSCLC: Merck has reported positive new data analysis from an ongoing multi-centre, single-arm, open-label Phase Ib trial (KEYNOTE-001) investigating Keytruda in previously treated patients with advanced NSCLC, who have not had previous treatment with a PD-1 inhibitor. Treatment with Keytruda results in an overall response rate (ORR) of 45.4% in patients with greater than or equal to 50% tumour expression of PD-L1 (n=73), meanwhile the ORR dropped to 16.5% in patients demonstrating 1-49% expression of PD-L1 (n=103), and 10.7% in patients with less than 1% expression (n=28). The overall patient population realised an ORR of 19.4% (n=495). With regards to progression-free survival (PFS) the PD-L1 sub-group with greater or equal to 50% PD-L1 expression demonstrated 6.3 months median PFS (mPFS; n=119), rising to 12.5 months in treatment-naïve patients (n=62). Patients with 1-49% expression demonstrated mPFS of 3.3 months (n=161), and those with less than 1% mPFS of 2.3 months (n=76). Median overall survival (OS) has not yet matured for the high-expression sub-group, but it was 8.8 months for the other PD-L1 sub-groups below 50% expression. Median duration of response was comparable across the different sub-groups - 12.4 months for the high expression (50%), 10.3 months for 1-49% expression, and not reached for less than 1%.

TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA(R) (pembrolizumab) in Solid Tumors

TetraLogic Pharmaceuticals Corporation and Merck announced that they have entered into an oncology clinical study collaboration. The companies will collaborate on a Phase 1 study to evaluate the safety and efficacy of birinapant, TetraLogic's SMAC-mimetic, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with relapsed or refractory solid tumors. The study is expected to begin in late 2015. KEYTRUDA and birinapant target different elements of cancer's block against the immune system. TetraLogic's birinapant (TL32711) is a potent, bivalent SMAC-mimetic that binds with differential affinity to multiple members of the IAP family in order to re-establish the immune system's ability to kill abnormal cells via an extracellular TNF signal. Merck's KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2. The proposed collaboration is based on preclinical data that suggest SMAC-mimetics have the potential to enhance existing immuno-oncology agents, such as KEYTRUDA. Under the terms of the agreement, TetraLogic and Merck, through subsidiaries, will collaborate on an initial Phase 1 dose-escalation study of birinapant in combination with KEYTRUDA in patients with relapsed or refractory solid tumors. TetraLogic will sponsor and fund the study and Merck will provide KEYTRUDA. The companies have formed a Joint Development Committee to collaboratively oversee the conduct of the study. Results from the study will be used to determine the path for further clinical development of the combination.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
6MK:GR €53.27 EUR -0.02

6MK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $158.99 USD -0.67
Amgen Inc $167.91 USD -1.26
Gilead Sciences Inc $103.70 USD -1.51
L'Oreal SA €175.75 EUR +0.75
Pfizer Inc $35.27 USD -0.09
View Industry Companies
 

Industry Analysis

6MK

Industry Average

Valuation 6MK Industry Range
Price/Earnings 14.1x
Price/Sales 3.9x
Price/Book 3.4x
Price/Cash Flow 13.7x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK & CO. INC., please visit www.merck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.